

CLL Global Virtual Town Hall

Thank you for your patience.
We will begin shortly.

Have questions for our panel?
Please email them to Production@theHCCollective.com



Questions?

Please send an email to
Production@theHCCollective.com

A video of today's Town Hall presentation will be
available at our website: cllglobal.org



• CHRONIC LYMPHOCYTIC LEUKEMIA •

Dr. William Wierda

President & CEO

CLL Global Research Foundation

Jane and John Justin Distinguished Chair in Leukemia
Research in Honor of Dr. Elihu Estey

Executive Medical Director

The University of Texas MD Anderson Cancer Center



• CHRONIC LYMPHOCYTIC LEUKEMIA •

Prof. Constantine Tam

Head of Lymphoma Service, Alfred Health

Professor of Haematology, Monash University



• CHRONIC LYMPHOCYTIC LEUKEMIA •

WHAT'S NEW IN CLL?



30 January 2025

William G. Wierda MD, PhD

Professor of Medicine

Section Head, CLL

Department of Leukemia

U.T. M.D. Anderson Cancer Center

Houston, TX USA



MEETING UPDATE

American Society of Hematology

ASH 2024



ASH 2024

- **Phase III first-line AV vs. AVO vs. FCR/BR – AMPLIFY (Beigene)**
- **Phase II first-line pirtobrutinib/venetoclax/obinutuzumab (MDACC)**
- **Phase I/Ib first-line zanubrutinib + sonrotoclax (Beigene)**
- **Phase II first-line VEN/OBIN + Atezolizumab (MDACC)**
- **Phase III pirtobrutinib vs. idela/R or BR (Lilly) for R/R CLL**
- **Phase I/II liso-cel + ibrutinib (BMS) for R/R CLL - TRANSCEND CLL 004**
- **Phase I study of BTK-degrader (NX-5948) (Nurix) for R/R CLL**
- **Phase I study of BTK-degrader (BGB-16673) (Beigene) for R/R CLL**
- **Phase II Epcoritimab (Genmab/AbbVie) for R/R CLL**




UPCOMING MEETINGS

European Hematology Association
2025 (June)

American Society of Clinical Oncology
2025 (June)

International Workshop on CLL
iwCLL 2025 (Sept)

American Society of Hematology
ASH 2025 (Dec)




THANK YOU

William G. Wierda MD, PhD

713-745-0428

wwierda@mdanderson.org

Variant (Non-C481S) BTK Mutations in Patients Treated with BTK Inhibitors for CLL



- Unlike the case of ibrutinib, where BTK C481S represents the majority of resistant mutations, treatment with second-generation and non-covalent BTKi are associated with newly described resistant BTK mutations both at the C481 site and at other sites.
- These mutations have clinical significance as they may confer resistance to multiple agents.

Q&A



Send questions to
Production@theHCCollective.com



• CHRONIC LYMPHOCYTIC LEUKEMIA •

Thank You For Joining!

Contact Us



Sam Pace
mcpace@cllglobal.org
(713) 745-1861



**Visit our website at cllglobal.org
to view slides from today's presentation**



**Follow us on Facebook at facebook.com/cllglobal
to keep up with the latest CLL news**



CLL Global Research Foundation
P.O. Box 301402, Unit 428
Houston, Texas 77230